Downregulation of Mcl-1 leads to sensitization of tumor cells to different treatment regimens in vitro, as shown for cholangiocarcinoma, chronic myelogenous leukemia, sarcoma and malignant melanoma [23-26]. This evidence concerns the gene MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive.